Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Can-Fite Biopharma Ltd (CANF)

Can-Fite Biopharma Ltd (CANF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,904
  • Shares Outstanding, K 1,333
  • Annual Sales, $ 3,820 K
  • Annual Income, $ -6,570 K
  • 60-Month Beta 1.57
  • Price/Sales 1.35
  • Price/Cash Flow N/A
  • Price/Book 0.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.65
  • Number of Estimates 2
  • High Estimate -0.25
  • Low Estimate -1.06
  • Prior Year -2.70
  • Growth Rate Est. (year over year) +75.93%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.27 +62.11%
on 11/08/19
4.95 -25.66%
on 12/02/19
+1.17 (+46.61%)
since 11/06/19
3-Month
1.90 +93.68%
on 10/02/19
4.95 -25.66%
on 12/02/19
+1.24 (+50.82%)
since 09/06/19
52-Week
1.90 +93.68%
on 10/02/19
24.30 -84.86%
on 03/20/19
-15.67 (-80.98%)
since 12/06/18

Most Recent Stories

More News
Can-Fite to Attend BioFIT 2019 Conference in Europe with Focus on Partnering Meetings for Namodenoson in NASH

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today the...

CANF : 3.68 (-4.91%)
CFBI : 11.30 (-0.70%)
Can-Fite Reports Third Quarter 2019 Financial Results & Provides Clinical Update

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced...

CANF : 3.68 (-4.91%)
CFBI : 11.30 (-0.70%)
Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on November 25, 2019

Can-Fite BioPharma Ltd. (NYSE American: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced its CEO...

CANF : 3.68 (-4.91%)
CFBI : 11.30 (-0.70%)
Can-Fite Granted Patents for its Sexual Dysfunction Drug

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today it...

CANF : 3.68 (-4.91%)
CFBI : 11.30 (-0.70%)
Can-Fite Granted U.S. Patent for Piclidenoson in the Treatment of Osteoarthritis, Positioning this Indication for Animal Health Market

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today the...

CANF : 3.68 (-4.91%)
CFBI : 11.30 (-0.70%)
Can-Fite Initiates Compassionate Use Program for Namodenoson in the Treatment of Liver Cancer, Enrolls and Treats Patients

--The Company recently completed a successful End-of-Phase II meeting with the U.S. FDA for a pivotal Phase III study in advanced liver cancer

CANF : 3.68 (-4.91%)
CFBI : 11.30 (-0.70%)
U.S. FDA Agreed with Can-Fite's Proposed Pivotal Phase III Trial Design to Support a New Drug Application Submission and Approval of Namodenoson in the Treatment of Liver Cancer

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today it...

CANF : 3.68 (-4.91%)
CFBI : 11.30 (-0.70%)
Can-Fite and Gebro Pharma holding European Conference on Development & Commercialization of Phase III Drug Candidate Piclidenoson in the Treatment of Rheumatoid Arthritis

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases and Gebro Pharma,...

CANF : 3.68 (-4.91%)
CFBI : 11.30 (-0.70%)
Can-Fite BioPharma Interview to Air on Bloomberg International on the RedChip Money Report

Can-Fite BioPharma Ltd. (NYSE American: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced an interview...

CANF : 3.68 (-4.91%)
CFBI : 11.30 (-0.70%)
Can-Fite Completes Patient Enrollment in Phase II NASH Study of Namodenoson(TM)

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today it...

CANF : 3.68 (-4.91%)
CFBI : 11.30 (-0.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade CANF with:

Business Summary

Can Fite Biopharma Ltd. is a biopharmaceutical company. It is focused on developing drugs for the treatment of cancer and autoimmune inflammatory diseases. The Company's lead drug candidate, CF101, is in clinical development for the treatment of autoimmune inflammatory diseases. Its CF102 drug candidate...

See More

Key Turning Points

2nd Resistance Point 4.05
1st Resistance Point 3.87
Last Price 3.68
1st Support Level 3.47
2nd Support Level 3.26

See More

52-Week High 24.30
Fibonacci 61.8% 15.74
Fibonacci 50% 13.10
Fibonacci 38.2% 10.46
Last Price 3.68
52-Week Low 1.90

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar